Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 22:15:1935-1943.
doi: 10.2147/DMSO.S365147. eCollection 2022.

Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease

Affiliations

Pro-Neurotensin as a Potential Novel Diagnostic Biomarker for Detection of Nonalcoholic Fatty Liver Disease

Amal A Mohamed et al. Diabetes Metab Syndr Obes. .

Abstract

Background and aims: Currently, liver biopsy is the gold standard method for diagnosis of non-alcoholic fatty liver severity. It is critical to develop non-invasive diagnostic method to diagnose nonalcoholic fatty liver rather than invasive techniques. Our case-control study was to address the value of circulating miRNA-122 and serum pro-neurotensin as a potential non-invasive biomarker for the diagnosis of non-alcoholic fatty acid diseases.

Methods: Clinical assessment, laboratory investigations, and anthropometric measurements were reported for 157 patients with proven NAFLD. Apparently, healthy participants (n=100) were enrolled as a control group. Serum samples were tested for micro-RNAs-122 and pro-neurotensin.

Results: Compared with the control subjects, both mi-RNA-122 and serum proneurotensin levels were increased in NAFLD (p<0.001) and at a cut-off ≥6.83, mi-RNA-122 had 51.0% sensitivity, 70.0% specificity to differentiate NAFLD from healthy controls, while serum proneurotensin had 80.0% sensitivity and 80.0% specificity at a cutoff ≥108.

Conclusion: The circulating pro-neurotensin might be used as a novel biomarker for diagnosis of patients with NAFLD, wherefore the integration of a circulating mi-RNA-122 and serum pro-neurotensin could be beneficial to diagnose NAFLD cases. Large-scale studies are needed to investigate the possible role of mi-RNA-122 and pro-neurotensin in the development, progression, and prognosis of NAFLD and NASH.

Keywords: MAFLD; NAFLD; biomarker; diagnosis; fatty liver; metabolic associated fatty liver disease; micro-RNA-122; nonalcoholic fatty liver disease; noninvasive; proneurotensin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest, financial or otherwise.

Figures

Figure 1
Figure 1
Box-and-whisker plot chart showing difference between groups regarding: (A) serum proneurotensin, (B) serum micro-RNA-122.
Figure 2
Figure 2
ROC curve for diagnosis of pro-neurotensin and microRNA 122 assay in NAFLD patients.

References

    1. Ahmed AM, Ghany MA, Hakeem GLA, et al. Assessment of vitamin D status in a group of Egyptian children with nonalcoholic fatty liver disease. Nutr Metab. 2016;13(1):1–6. - PMC - PubMed
    1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. doi:10.1038/nrgastro.2017.109 - DOI - PubMed
    1. Mohamed AA, Elsaid OM, Amer EA, et al. Clinical significance of SNP (rs2596542) in histocompatibility complex class I-related gene A promoter region among hepatitis C virus related hepatocellular carcinoma cases. J Adv Res. 2017;8(4):343–349. doi:10.1016/j.jare.2017.03.004 - DOI - PMC - PubMed
    1. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver dis- ease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820–1832. doi:10.1002/hep.23594 - DOI - PubMed
    1. Mohamed AA, Ahmed HH, ElSadek SM, et al. A study of leptin and its gene 2548 G/A Rs7799039 single-nucleotide polymorphisms in Egyptian children, a single-center experience. Clin Res Hepatol Gastroenterol. 2021;45:101724. doi:10.1016/j.clinre.2021.101724 - DOI - PubMed